Ameriprise Financial Inc. purchased a new position in shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) during the first quarter, Holdings Channel reports. The fund purchased 130,100 shares of the biopharmaceutical company’s stock, valued at approximately $1,431,000.

A number of other large investors also recently made changes to their positions in SCMP. LSV Asset Management boosted its stake in shares of Sucampo Pharmaceuticals by 11.4% in the first quarter. LSV Asset Management now owns 2,346,418 shares of the biopharmaceutical company’s stock worth $25,810,000 after buying an additional 239,200 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Sucampo Pharmaceuticals by 107.3% in the first quarter. Bank of New York Mellon Corp now owns 367,691 shares of the biopharmaceutical company’s stock worth $4,044,000 after buying an additional 190,292 shares during the period. State Street Corp boosted its stake in shares of Sucampo Pharmaceuticals by 32.9% in the fourth quarter. State Street Corp now owns 581,835 shares of the biopharmaceutical company’s stock worth $7,882,000 after buying an additional 143,906 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Sucampo Pharmaceuticals by 7.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,559,433 shares of the biopharmaceutical company’s stock worth $21,130,000 after buying an additional 103,986 shares during the period. Finally, Bowling Portfolio Management LLC bought a new stake in shares of Sucampo Pharmaceuticals during the first quarter worth $531,000. 57.00% of the stock is owned by hedge funds and other institutional investors.

Sucampo Pharmaceuticals, Inc. (NASDAQ SCMP) opened at 10.95 on Friday. Sucampo Pharmaceuticals, Inc. has a 1-year low of $9.30 and a 1-year high of $17.55. The firm has a market capitalization of $508.78 million, a price-to-earnings ratio of 18.25 and a beta of 1.46. The firm has a 50-day moving average of $10.28 and a 200-day moving average of $11.25.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last posted its quarterly earnings results on Wednesday, May 3rd. The biopharmaceutical company reported $0.23 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.28 by $0.05. Sucampo Pharmaceuticals had a return on equity of 43.27% and a net margin of 11.36%. The business had revenue of $56.30 million during the quarter, compared to the consensus estimate of $54.15 million. During the same quarter in the previous year, the business posted $0.21 earnings per share. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, analysts expect that Sucampo Pharmaceuticals, Inc. will post $1.04 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/07/16/130100-shares-in-sucampo-pharmaceuticals-inc-nasdaqscmp-acquired-by-ameriprise-financial-inc.html.

SCMP has been the subject of a number of research reports. Jefferies Group LLC set a $13.00 price target on shares of Sucampo Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, April 20th. Mizuho reissued a “buy” rating and issued a $14.00 price target on shares of Sucampo Pharmaceuticals in a research report on Tuesday, April 4th. Maxim Group reissued a “buy” rating and issued a $21.00 price target on shares of Sucampo Pharmaceuticals in a research report on Thursday, April 13th. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Finally, ValuEngine cut shares of Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $17.00.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Want to see what other hedge funds are holding SCMP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP).

Institutional Ownership by Quarter for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.